Skip to main content

Table 7 Univariate analysis with Log-rank test

From: Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas

Factor n 3-y LRRFS 3-y DMFS 3-y DFS 3-y OS
Events(n) Survival P* Events(n) Survival P* Events(n) Survival P* Events(n) Survival P*
Age
  < 50 187 8 96.0% 0.127 9 94.9% 0.049 19 89.2% 0.002 14 91.6% 0.008
  ≥ 50 109 9 92.8%   12 90.9%   26 79.9%   20 82.8%  
Gender
 Male 215 10 97.1% 0.207 19 93.9% 0.057 35 88.3% 0.397 27 88.0% 0.347
 Female 81 7 91.5%   2 97.0%   10 87.6%   7 89.2%  
T Stage
 T1 88 2 98.9% 0.034 6 93.1% 0.855 9 88.6% 0.045 7 92.0% 0.321
 T2 89 3 96.4%   6 94.4%   10 89.8%   9 93.2%  
 T3 68 8 86.2%   4 91.9%   13 79.8%   10 81.3%  
 T4 51 4 90.3%   5 87.5%   13 71.6%   8 79.9%  
Node category
 N- 43 2 95.0% 0.762 2 94.9% 0.537 4 90.1% 0.287 4 90.5% 0.664
 N+ 253 15 97.2%   19 94.8%   41 82.9%   30 88.0%  
N Stage
 N0 43 2 95.0% 0.625 2 94.9% 0.451 4 90.1% 0.401 4 90.5% 0.876
 N1 102 4 95.7%   7 92.1%   14 85.2%   11 90.0%  
 N2 132 9 95.1%   12 91.1%   25 84.6%   17 87.1%  
 N3 19 2 88.8%   0 100.0%   2 88.8%   2 86.1%  
UICC Stage
 I 15 0 100.0% 0.125 0 100.0% 0.273 0 100.0% 0.019 0 100.0% 0.121
 II 76 1 98.6%   3 96.0%   5 93.3%   5 96.0%  
 III 134 11 92.6%   13 90.3%   26 83.9%   20 84.4%  
 IV 71 5 91.8%   5 90.9%   14 78.0%   9 84.4%  
Induction chemotherapy was performed or not in stage III-IVpatients
 No 97 8 89.8% 0.608 9 88.8% 0.650 22 74.8% 0.172 18 79.9% 0.058
 Yes 108 8 91.5%   9 91.5%   18 82.6%   11 88.3%  
  1. Abbreviation: 3-y LRRFS 3-year local-regional relapse free survival; 3-y DMFS 3-year distant metastasis free survival; 3-y DFS 3-year disease free survival; 3-y OS 3-year overall survival
  2. *P-values were calculated using the unadjusted log–rank test